Panel Discussion: Available Treatments and Most Active Target/Payload Combination

Kathleen Moore, MD
# Properties of select ADCs in gynecologic oncology

<table>
<thead>
<tr>
<th>ADC</th>
<th>Target</th>
<th>Linker</th>
<th>DAR</th>
<th>Payload</th>
<th>Class</th>
<th>Bystander effect</th>
<th>Disease of interest or approved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mirvetuximab soravtansine</strong>&lt;sup&gt;1-3&lt;/sup&gt;</td>
<td>Folate receptor α</td>
<td>Sulfo-SPDB (cleavable)</td>
<td>3–4</td>
<td>DM4</td>
<td>Maytansinoid</td>
<td>Yes</td>
<td>Ovarian and endometrial cancer</td>
</tr>
<tr>
<td><strong>Tisotumab vedotin</strong>&lt;sup&gt;4-6&lt;/sup&gt;</td>
<td>Tissue factor (CD142)</td>
<td>Valine-citrulline (cleavable)</td>
<td>4</td>
<td>MMAE</td>
<td>Auristatin analogs</td>
<td>Yes</td>
<td>Cervical and ovarian cancer</td>
</tr>
<tr>
<td><strong>STRO-002</strong>&lt;sup&gt;7,8&lt;/sup&gt;</td>
<td>Folate receptor α</td>
<td>Valine-citrulline (cleavable)</td>
<td>4</td>
<td>SC209 (hemiasterlin)</td>
<td>Folate receptor α</td>
<td>Yes</td>
<td>Ovarian and endometrial cancer</td>
</tr>
</tbody>
</table>

- **Bystander effect:** Yes
- **Disease of interest or approved:**
  - **Mirvetuximab soravtansine:** Ovarian and endometrial cancer
  - **Tisotumab vedotin:** Cervical and ovarian cancer
  - **STRO-002:** Ovarian and endometrial cancer

Other antigen targets under clinical investigation include B7-H4, CD166, HER2, mesothelin, MUC16, NOTCH3, PTK7, TROP2<sup>1, 9-11</sup>

---

ADC, antibody-drug conjugate; CD, cluster of differentiation; DAR, drug-to-antibody ratio; DM4, maytansinoid DM4; HER2, human epidermal growth factor receptor 2; MMAE, monomethyl auristatin E.